|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2011-4-18
|
|
pubmed:abstractText |
Chemoradiation therapy (CRT) is now widely recognized as bladder-preserving therapy for muscle-invasive bladder cancer (MIBC). However, some patients who fail CRT may miss the chance to be cured by cystectomy. Therefore, it is important to select patients with MIBC who are expected to have a good response to CRT. Several reports indicate that the excision repair cross-complementing group 1 (ERCC1) gene is associated with resistance to cisplatin and radiation therapy. In this study, we examined the correlation between ERCC1 and CRT in vitro and in vivo in bladder cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AbeToyofumiT,
pubmed-author:HatanoKojiK,
pubmed-author:HoshidaYoshihikoY,
pubmed-author:ItataniHiroakiH,
pubmed-author:KakutaYoichiY,
pubmed-author:KawashimaAtsunariA,
pubmed-author:MukaiMasatoshiM,
pubmed-author:NagaharaAkiraA,
pubmed-author:NakaiYasutomoY,
pubmed-author:NakayamaMasashiM,
pubmed-author:NishimuraKazuoK,
pubmed-author:NonomuraNorioN,
pubmed-author:OkaDaizoD,
pubmed-author:TakayamaHitoshiH,
pubmed-author:YoshiokaToshiakiT
|
|
pubmed:copyrightInfo |
©2010 AACR.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2561-9
|
|
pubmed:meshHeading |
pubmed-meshheading:21177407-Aged,
pubmed-meshheading:21177407-Aged, 80 and over,
pubmed-meshheading:21177407-Antineoplastic Agents,
pubmed-meshheading:21177407-Blotting, Western,
pubmed-meshheading:21177407-Cell Line, Tumor,
pubmed-meshheading:21177407-Cell Survival,
pubmed-meshheading:21177407-Cisplatin,
pubmed-meshheading:21177407-Combined Modality Therapy,
pubmed-meshheading:21177407-DNA-Binding Proteins,
pubmed-meshheading:21177407-Endonucleases,
pubmed-meshheading:21177407-Female,
pubmed-meshheading:21177407-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:21177407-Humans,
pubmed-meshheading:21177407-Immunohistochemistry,
pubmed-meshheading:21177407-Male,
pubmed-meshheading:21177407-Middle Aged,
pubmed-meshheading:21177407-Muscles,
pubmed-meshheading:21177407-Neoplasm Invasiveness,
pubmed-meshheading:21177407-Prognosis,
pubmed-meshheading:21177407-RNA Interference,
pubmed-meshheading:21177407-Radiotherapy,
pubmed-meshheading:21177407-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:21177407-Treatment Outcome,
pubmed-meshheading:21177407-Urinary Bladder Neoplasms
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer.
|
|
pubmed:affiliation |
The Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan.
|
|
pubmed:publicationType |
Journal Article
|
